CURRICULUM VITAE

LORI A. FISCHBACH, M.P.H., PH.D.
Supervising Epidemiologist
Division of Disease Control and Injury Prevention
LA County Department of Public Health

Email: LFischbach@ph.lacounty.gov
Cell Phone: 213-563-5322

Education

December, 1997	Ph.D. University of California, Los Angeles, Epidemiology
June, 1990	M.P.H. University of California, Los Angeles, Biostatistics
May, 1986	B.S. University of Arizona, Nutritional Sciences - Dietetics

Special Skills and Additional Training

- Fluent in English and Spanish
- Experience using SAS, BMDP, SPSS, STATA, Comprehensive Meta-analysis, GAUSS, REDCap, Dagitty, Simulations for COVID-19 projections, and other statistical software
- Additional Training:
    - Machine Learning
    - Meta-analyses
    - Network-meta-analyses
    - Handling missing data
    - Data Visualization
    - E-values
    - Mediation Analyses
    - Program Evaluation
    - COVID-19 (Emory University and the CDC)

Academic and Professional Positions

2022-current	***Supervising Epidemiologist*** Division of Disease Control and Injury Prevention Los Angeles County Public Health Department
2020-current	***Supervising Epidemiologist*** Los Angeles County Public Health Department - Contractor
2013 – 2020	***Director of the PhD program in Epidemiology*** University of Arkansas for Medical Sciences
2015 – 2017	***Interim Chair for the Department of Epidemiology*** University of Arkansas for Medical Sciences
2015 – 2017	***Adjunct Faculty, Office of Global Health*** University of Arkansas for Medical Sciences
2012 – 2020	***Associate Professor, Department of Epidemiology*** University of Arkansas for Medical Sciences
2010 – 2012	***Associate Professor, Department of Epidemiology*** University of North Texas, School of Public Health
2009 – 2010	***Vice Chair, Department of Epidemiology*** University of North Texas, School of Public Health
2004 – 2010	***Assistant Professor of Epidemiology*** University of North Texas, School of Public Health
2003 – 2004	***Adjunct Assistant Professor*** University of Texas Southwestern Medical Center
1998 – 2004	***Assistant Professor*** University of Texas – Houston Health Science Center School of Public Health Dallas Campus at UT Southwestern Medical Center
1997 – 1998	***Post-Doctoral Faculty Research Associate*** Arizona Cancer Center, University of Arizona
1990 – 1993	***Teaching Assistant, Department of Epidemiology*** University of California, Los Angeles (by semester)
1990 – 1993	***Statistical Consultant, Biomathematics and Statistical Consulting Center*** University of California, Los Angeles
1988 – 1992	***Staff Research Associate, Latinas and A.I.D.S. Research Project*** University of California, Los Angeles and University of Southern California

Honors and Awards

Teaching and Mentoring Awards (Student Names are highlighted)

Faculty Excellence in Teaching Award for the College of Public Health, University of Arkansas for Medical Sciences, 2018.

2nd Place in the Student Poster Competition. **Powell T**, **Ojha RP**, Singh KP**, Fischbach LA.** Histologic subtype and pancreatic cancer survival: addressing uncontrolled confounding. American College of Epidemiology Conference, 2009, Washington, DC.

Best Paper in Statistics. **Priest EL**, Adams B, **Fischbach LA**. Easier exploratory analysis for Epidemiology: A grad student how-to-paper. SAS Global Forum, 2009, Washington D.C.

1st Place in the Student Poster Competition. **Ojha RP,** Singh KP, Felini MK, **Evans EL, Fischbach LA.** Best subset selection and trend analysis for optimizing the discriminatory accuracy of diagnostic models. American College of Epidemiology Conference in Tucson, AZ, 2008.

1st Place in the Student Poster Competition. **Broussard CS**, Goodman KJ, Phillips CV, Day RS, Aragaki CC, Smith MA, **Fischbach LA.** Antibiotics taken for other illnesses and incidence of *Helicobacter pylori* infection in children. American College of Epidemiology Conference in Fort Lauderdale, FL, 2007.

Most Outstanding Teacher Award. University of Texas Health Science Center. Dallas campus, 2001.

Honorable Mention for the "Supervivir" Program – Colombian Health and Education Ministry

Public Health Service Awards

Faculty Excellence in Public Service Award for the College of Public Health – University of Arkansas for Medical Sciences, 2017.

Delta Delta Delta Community Service Project Award

Other Selected Honors and Awards

***Delta Omega Honorary Society of Public* Health,** 2017

Gold Award at the Panamerican Digestive Disease Week, 2016, Cartagena, Colombia

Outstanding Research Award for the School of Public Health, University of North Texas Health Science Center, 2006

Excellence in Research Award (2003-2004)

Excellence in Research Award (2002-2003)

Excellence in Scholarship Award (2002-2003)

Excellence in Scholarship Award (2001-2002)

Excellence in Scholarship Award (2000-2001)

Cancer Research Foundation of America Fellowship

Fulbright Scholar (Colombia, South America)

National Cancer Institute Cancer Training Fellowship

University Fellowship (University of California, Los Angeles)

University of Arizona President's Award for Academic Excellence

PHI KAPPI PHI (University of Arizona)

Delta Delta Delta Community Service Award (University of Arizona)

Gamma Sigma Delta Senior of the Year (University of Arizona)

Shamrock Food and the McClelland Family Scholarship (University of Arizona)

Bank of America Award for Math and Sciences

Professional Societies (previous and current membership)

American Public Health Association

Society for Epidemiological Research

American College of Epidemiology

American Gastroenterology Association

Canadian Helicobacter Study Group

Public Health International Association

Teaching

Courses taught at the University of Arkansas for Medical Sciences

Epidemiology I

Advanced Integration of Epidemiologic Concepts and Methods

Introduction to Epidemiologic Methods (for the Stead undergraduate scholars)

Advanced Epidemiologic Methods

Advanced Epidemiologic Methods Laboratory

Clinical Epidemiology

Directed Research Studies

Courses taught at other academic institutions

Advanced Methods in Epidemiology I. University of North Texas Health Science Center.

Advanced Methods in Epidemiology II. University of North Texas Health Science Center.

Quantitative Epidemiologic Methods. University of North Texas Health Science Center.

Experimental Methods in Epidemiology. University of North Texas Health Science Center.

Reviewing Epidemiologic Evidence. University of North Texas Health Science Center.

Cancer Epidemiology. University of North Texas Health Science Center.

Doctoral Independent Study in Epidemiology. University of North Texas Health Science Center.

Independent Study in Epidemiology. University of North Texas Health Science Center.

Review and Synthesis of Epidemiologic Evidence. UT Houston SPH – Dallas Regional Campus.

Theory and Practice of Epidemiology. University of North Texas Health Science Center.

Advanced Epidemiologic Methods. University of Texas Houston – Dallas Regional Campus.

Experimental Methods and Clinical Trials. The University of Texas Southwestern Medical Center Patient-Oriented Research Program, and UT Houston SPH – Dallas Regional Campus.

Thesis Preparation Seminar. UT Houston SPH – Dallas Regional Campus.

Applied Data Analysis. UT Houston SPH – Dallas Regional Campus.

Introduction to Statistical Software. UT Houston SPH – Dallas Regional Campus.

Clinical and Prevention Trials. UT Houston SPH – Dallas Regional Campus.

Patient Oriented Clinical Research Training Project. UT – Southwestern Medical Center.

Other classes taught in seminars/courses at the University of Arkansas for Medical Sciences

Special Topics – "Machine Learning" (2 class sessions)

Chronic Disease Epidemiology – "Meta-analyses" (2 class sessions)

Special Topics – "Meta-Analysis/Network Meta-analysis" (2 class sessions)

Interprofessional Education Movie Night Event– "Living on a Dollar a Day" (Student Learning Module)

Public Health Seminar – "Should corpus-predominant gastritis be used to identify *H pylori* positive patients at high risk for progression in the gastric precancerous process?"

Special Topics Series – "Critical Reviews of Epidemiologic Evidence" (3 class sessions)

Public Health Seminar – "Treatment of *Helicobacter pylori*"

Health Research, Policy and Health Promotion Seminar – "The Treatment of *Helicobacter pylori*: Using Evidence from Meta-analyses and Systematic Reviews to Change Clinical Guidelines."

Other class sessions taught at other institutions in English

Los Angeles Department of Health – Training on Creating Epidemiologic Curves in Excel and SAS (3 sessions)

Arkansas Department of Health Grand Rounds – "Training cosmetology students in Arkansas to help dermatologists prevent skin cancer and detect melanomas earlier."

Biomedical Sciences – *"*Meta-analysis in Evidence-Based Medicine*"* at the University of North Texas Health Science Center

Gastroenterology web seminar for physicians across the United States – "Common Challenges in the Treatment of *Helicobacter pylori*."

Gastroenterology Seminar – *"*Treatments for Helicobacter pylori*" at Baylor* College of Medicine; Houston, Texas.

Applied Data Analysis in Epidemiology – "Meta-analysis"

Advanced Epidemiologic Methods II – "Meta-analysis" (2 lectures plus an assignment) at the University of Texas Houston, Health Science Center in Houston, Texas.

Introduction to Epidemiology – "Measures of Disease Frequency" at the University of Texas Houston Health Science Center, Houston, Texas.

Experimental Methods –University of Texas Houston Health Science Center, Houston, Texas.

"Meta-analysis"

"International Clinical Trials, and Chemoprevention Trials"

Grand Rounds in Public Health Research – "Public Health Research".

Epidemiology Doctoral Seminar – "Meta-analysis" at the University of Texas Houston Health Science Center in Houston, Texas.

Public Health Elective

"Conducting Public Health Research in Colombia" at Southern Methodist University, Department of Anthropology, Dallas, Texas.

"Conducting Public Health Research in a Developing Country" at the University of Texas Southwestern Medical Center, School of Medicine, Dallas, Texas.

"A Global Look at Medicine" at UT Southwestern Medical Center, School of Medicine, Dallas, Texas.

Introduction to Environmental *Sciences – "Environmental Aspects of Infectious Disease" at the* University of Texas Houston SPH, Dallas Regional Campus.

Introduction to Epidemiology – Graduate Teaching Assistant, University of California, Los Angeles.

Methods in Epidemiology – Graduate Teaching Assistant, under Hal Morgenstern at the University of California, Los Angeles.

Student Advising

Student Mentoring Programs

Stead Scholar Program (for Undergraduates in Arkansas)
University of Arkansas for Medical Sciences

Complementary and Alternative Medicine Short-Term Research Rotation (CAMSTRR)
University of North Texas, Health Science Center

McNair, Summer Scholars Program (underrepresented groups or for first generation undergraduates with financial need) University of North Texas, Health Science Center, Fort Worth, Texas

Patient-Oriented Research Program
UT Southwestern Medical Center, Dallas, Texas

Student International Health Interest Group Faculty Advisor
UT Southwestern Medical Center, Dallas, TX

Service to the University – Committee Membership

University of Arkansas for Medical Sciences

2019-2020	Chancellor's Appeal Board
2019-2020	Disability Division of Diversity Equity and Inclusion Subcommittee

2019-2020	Faculty Affairs Committee
2019-2020	Faculty Retention Committee
2018-2020	Faculty Search Committee – Epidemiology **(Chair)**
2018-2019	Seeking Educational Equity and Diversity (SEED) Group
2018	Research Day Judge
2016 – 2020	Student Grievance Committee
2016 – 2017	Academic Standards Committee
2016 – 2020	Doctoral Director's Committee
2016	College of Public Health Advisory Council
2015	Office of Global Health, Director Search
2015 – 2017	Dean's Executive Committee
2013 – 2020	Ph.D. Advisory Committee in Epidemiology (**Chair**)
2013 – 2015	Inter-professional Education (IPE) Committee
2013	Cancer Epidemiology Faculty Search Committee (**Chair**)
2012 – 2014	Academic Standards Committee
2012 – 2013	Epidemiology Faculty Search Committee (**Chair**)
2012 – 2013	Staff Assistant Search Committee
2013	University of Arkansas for Medical Sciences Diversity Committee

University of North Texas Health Science Center

2011 – 2012	Faculty Senate
2011 – 2012	Faculty Grievance and Appeal Committee
2011 – 2012	Public Health Practice Committee
2009 – 2011	PhD Committee
2009 – 2010	DrPH Admissions Committee
2009 – 2010	DrPH Committee Member

2007 – 2008	Institutional Review Board
2005 – 2007	CEPH Self-Study Steering Committee
2005 – 2007	Planning and Evaluation Committee
2005 – 2006	Grant Peer Reader Committee
2005 – 2006	School-wide Chair Search Committee
2005 – 2006	Epidemiology Faculty Search Committee
2004 – 2005	School Wide Faculty Search Committee

University of Texas Health Science Center, Dallas Campus

2003 – 2004	Interfaculty Council
2002	Peer Review Committee
2002 – 2003	Student Research Grants Committee UT Houston School of Public Health
2002	Faculty Affairs Committee – Dallas Representative
1998 – 2003	Dallas Biometry Faculty Search
2002	Dallas Behavioral Science Faculty Search Library Director Search Committee UT Southwestern Medical Center
2000 – 2002	Library Advisory Committee UT Southwestern Medical Center
1999 – 2000	Research Advisory Committee Member for the HIV Research Group UT Southwestern Medical Center
1999	Admissions Committee
1998 – 1999	Dallas Management and Policy Faculty Search
1998	Dallas Environment Science Faculty Search Committee

Other University Service

2018-2020	Orientation Presenter
2017-2018	Patient-Scientist Academy Translational Research Institute University of Arkansas for Medical Sciences
2016 – 2017	Culminating Experience Poster Presentation Evaluator
2016	Global Public Health Panel University of Arkansas for Medical Sciences
2016	Speaker, Community Information Session for Community Partners Translational Research Institute University of Arkansas for Medical Sciences
2016	Gastrointestinal Disease Oriented Group Winthrop P Rockefeller Cancer Institute University of Arkansas for Medical Sciences
2016	Translational Research Institute Mock Study Section University of Arkansas for Medical Sciences
2007 – 2009	Admissions Coordinator for the Department of Epidemiology

Editorial Review Service

American Journal of Gastroenterology

Cochrane Upper Gastrointestinal and Peptic Ulcer Disease group

BMC Gastroenterology

Clinical Gastroenterology and Hepatology

Helicobacter

World Journal of Gastrointestinal Pharmacology and Therapeutics

Gastroenterology

Clinical and Experimental Medicine

Lancet

New England Journal of Medicine

Alimentary Pharmacology and Therapeutics

American Journal of Epidemiology

Cancer Epidemiology, Biomarkers & Prevention

Annals of Epidemiology

Epidemiologic Reviews
International Journal of Cancer
Clinical and Experimental Medicine
Journal of Antimicrobial Chemotherapy
Journal of Clinical Outcomes Management
American Public Health Association
Epidemiological Perspectives and Innovations
American Journal of Gastroenterology
Controlled Clinical Trials
Medical Care
Archives of Internal Medicine
Annals of Internal Medicine
Gastroenterology & Hepatology
Clinical Therapeutics
Journal of Clinical Gastroenterology
Pediatric Infectious Disease Journal
Digestive and Liver Disease
American Gastroenterology Association – Epidemiologic Section
American Gastroenterology Association
The Cochrane Collaboration – Cochrane Upper Gastrointestinal and Pancreatic Diseases
Group Medical Science Monitor - International Reviewer's Panel
PLOS ONE
Evidence-Based Complementary and Alternative Medicine
Gastroenterology Research and Practice

Editorial Boards

2013 – 2018	Associate Editor - BMC Gastroenterology
2009	Editorial Board, World Journal of Gastrointestinal Pharmacology & Therapeutics
2009	Editorial Board and Consultant for Epidemiological Focus
2004 – 2005	Associate Editor - Epidemiological Perspectives and Innovations (EPI)
2004 – 2006	Editorial Board - Public Health International Bulletin

Service on Study Sections

2018 – 2020	Arkansas Center for Health Disparities (ARCHD) Pilot Grant Review Committee
2017	Scientific Quality Reviewers for the Clinical and Translational Science Award (CTSA) Consortium Scientific Review Committee (SRC)
2016	Center for Disease Control/ NIOSH World Trade Center Research Study Section Atlanta, June 28-29
2016 – 2017	Member of the Arkansas Cancer Coalition Grant Study Section
2008	Initiative Pilot Grant Reviewer North and Central Texas Clinical and Translational Science
2006 – 2009	Abstract Review Committee Member American Gastroenterological Association Esophageal, Gastric & Duodenal Disorders section
2004	The Wellcome Trust's Collaborative Research Initiative Grant
2004	University of Texas, Arlington Grant Proposals
2002	Infectious Disease Abstract Review Committee American Public Health Association Meeting
2000 – current	Cochrane Upper Gastrointestinal and Pancreatic Diseases Group

Other Professional & Community Service Activities in English

Student Names are highlighted

2020 - current	SARS-CoV-2 simulator to project spread and deaths in Arkansas due to the coronavirus. This is used by the UAMS Chancellor, the Secretary of Health and the Governor for the State of Arkansas and Los Angeles County Public Health https://publichealth.uams.edu/2020/06/15/modeling-the-covid-19-pandemic-in-arkansas/
2020	Consultant for the UAMS, Executive Associate Dean for Clinical Affairs regarding the SARS-CoV-2 pandemic.
2020	Consultant to the Arkansas Department of Health using our SARS-CoV-2 simulator.

2019	Expert Panel for Redhill Pharmaceuticals for FDA approval of *Helicobacter pylori* treatment
2017-current	Data Safety Monitoring Committee for the GI1527 Chemoprevention of Gastric Carcinogenesis Clinical Trial in Puerto Rico and Honduras
2018-2019	Faculty Marshall for UAMS Commencement Ceremony
2018	Research Day Judge
2018	Arkansas State Science and Engineering Fair – Community Health Judge
2018	Central Arkansas Science and Engineering Fair – Health Science Judge
2017	Ramp Marshall for UAMS Commencement Ceremony
2017	Consultant for Arkansas Department of Health CDC/CSTE Applied Epidemiology Fellow, Virgie Fields, for an Influenza VE meta-analysis
2015	Toronto Consensus Group The North American Consensus Recommendations for *Helicobacter pylori* Treatments Toronto, Canada
2015 – 2018	Arkansas Cancer Coalition Summit Planning Committee Arkansas Cancer Coalition, Little Rock, AR
2016	Stead Scholar Selection Committee Arkansas Department of Health, Little Rock, AR
2012	Consultant for HealthPoint Ltd to examine the efficacy of Xenaderm for pressure ulcer healing.
2011	Faculty Panel for Live Broadcast to physicians in the United States: *Common Challenges in the Treatment of H pylori*.
2010	Selected as a State-of-the-Art Presentation *Clinical Dilemmas in the Treatment of Helicobacter pylori* American Gastroenterology Association at Digestive Disease Week (Taped and distributed to physicians around the world)
2010	British Medical Association Commissioned Systematic Review (Medical Letter) Treatments for *Helicobacter pylori*
2009	Expert Consultant: Comment on FDA guidance on clinical trials of drugs for *H pylori* for Clinical Trials Advisor/Drug Industry Daily

2009	Chair, *Helicobacter pylori*: Diagnosis, Treatment and Antimicrobial Resistance Committee American Gastroenterology Association Esophageal, Gastric & Duodenal Disorders section
2009	Co-Chair, American Gastroenterology Association Research Forum "Novel Treatment Strategies for *Helicobacter pylori*" Chicago.
2009	Consultant: Treatment for *Helicobacter pylori* using Nitazoxanide, Doxycycline, Levofloxacin, and Esomeprazole in an immigrant population in the United States.
2009	Statewide School Health Surveillance Workgroup – Texas
2009	Pertussis Surveillance with Diana Cervantes Tarrant County Public Health Department
2009	Influenza Surveillance Programs in Day Care Settings with Tabatha Powell Tarrant County Public Health Department
2008	Treatments for *Helicobacter pylori* for The GI Research Forum Baylor College of Medicine
2008	Co-Chair of the American Gastroenterology Association Research Forum *Optimal Strategies for H pylori Diagnosis and Treatment*. San Diego, CA
2008	School of Public Health Representative Texas IRB Coordination Group Texas Department of State Health Services & Schools of Public Health
2006 – 2008	Consultant: Randomized field intervention trial of *H. pylori* eradication to reduce iron deficiency among children in El Paso, Texas
2006	Consultant: Cochrane Collaboration with Ford AC, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in *Helicobacter pylori* positive patients (Cochrane Review).
2005	Canadian Helicobacter Study Group Consensus Panel Consensus Conference – The Effect of Drug Resistance on Treatments Montreal, Canada
2004	Canadian Helicobacter Study Group Consensus Panel Consensus Conference – Pediatric Treatments Ottawa, Canada
2004 – 2007	Wish Granter for Make-A-Wish Foundation, Dallas, Texas
2004	Canadian Helicobacter Study Group Consensus Panel Consensus Conference – Quadruple Therapy Ottawa, Canada
2003 – 2005	Member of the Canadian Helicobacter Study Group

2003	Associated Press Interview: Participant in Press Conference on Breast Feeding and PBDEs
2003	Unpaid Consultant for Sander van Zanten for *H pylori* treatment effectiveness worldwide – Presentation in Maui, HI.
2002	Associated Press Interview: Participant in Press Conference on Breast Feeding and PBDEs
2003	Consultant for Namish Vakil on *H. pylori* treatment effectiveness worldwide. Presentation in Maui, HI.
2002-2003	Consultant for Sally Vernon on a Meta-analysis to look at the Sensitivity and Specificity of Papanicolaou Smears and Mammagraphy self-reports UT Houston, School of Public Health
2002	Research Interest Group Simmons Cancer Center at UT Southwestern Medical Center
2001	Medisend: Together with students from the UTHSPH Dallas satellite, we prepared medical supplies to be sent to clinics in developing countries.
2001	Consultant for Karen Goodman and Myles Cockburn's manuscript: "The role of epidemiology in understanding the health effects of *Helicobacter pylori,*" published in Epidemiology 12:266-71, 2001.
2000 – 2005	Advisory Board for Asthma in Public Schools: Improving Asthma Outcomes in Children, Dallas, TX
2000	Statistical Consultant for Mark Feldman and Bryon Cryer's manuscript, "Time course inhibition of gastric and platelet COX activity by acetylsalicylic acid in humans.
2000 – 2004	Consultant for the Adult Survivors of Childhood Leukemia Projects University of Texas Southwestern Medical Center, Dallas, TX
1998	*Helicobacter pylori* and Epidemiology Committee American Gastroenterology Association
1998-1999	Consultant for Dr Schecter to study dioxin levels in blood and milk. (Local)
1998	Associated Press Interview "The role of Selenium in the prevention of prostate and other cancers"
1998	Representative for the University of Texas, Houston, School of Public Health at the Community Partners for Public Health State Level Meeting

Professional and Community Service Activities in Spanish

2020	Consultant for the Associate Dean of the College of Public Health – Spanish Translations for the COVID-19 Arkansas Pandemic Poll Survey.
2020	Contact tracing in Spanish.
2017	*Cancer Prevention in Nariño, Colombia*. Keynote Presentation. 1st Annual Departmental Cancer Prevention Convention in Nariño, Colombia.
1998	Cancer Prevention and Screening –- Project Ayuda, Tucson, AZ
1993	*Helicobacter pylori* Infection: Associated Diseases. Pasto, Colombia
1995	Seminar on HIV Transmission –- Free Clinics in Los Angeles, California
1986-1988	Prevention of the Ten Leading Causes of Childhood Morbidity and Mortality Community Workshops –- Bogotá, Colombia
1986-1988	Pre-School Teacher Founded and taught at a pre-school in a low-income barrio. Bogotá, Colombia.

Leadership Positions

University of Arkansas for Medical Sciences

2018 – 2020	Chair, Faculty Search Committee, Epidemiology
2015 – 2017	Interim Chair, Department of Epidemiology
2013 – 2020	Director, PhD Program in Epidemiology
2013 – 2020	Chair, Ph.D. Program Advisory Committee
2012-2013	Chair, Cancer Epidemiology Faculty Search Committee

Other Leadership Positions

2009 – 2010	Vice Chair, Department of Epidemiology University of North Texas Health Science Center
2009	Chair, *Helicobacter pylori*: Diagnosis, Treatment and Antimicrobial Resistance Committee, American Gastroenterology Association Institute Council, Esophageal, Gastric & Duodenal Disorders section.

2009 Co-Chair, American Gastroenterology Association Research Forum
Novel Treatment Strategies for Helicobacter pylori.
Chicago, IL.

2008 Co-Chair, American Gastroenterology Association Research Forum
Optimal Strategies for H pylori Diagnosis and Treatment
San Diego, CA

Peer-Reviewed Publications

Student Names are highlighted

Fischbach L, Civen R, Boyd H, Flores D, Cloud J, Smith LV, King J, Alvarez F, Kuo T. Factors influencing COVID-19 vaccine acceptance in the workplace: Results from a rapid survey at 2 corporations in Los Angeles County, California, 2021. Public Health Reports 2022 Nov-Dec;137(6):1207-1216. doi: 10.1177/00333549221118086. Epub 2022 Aug 25. ***Impact Factor: 3.268***

Cardenas VM, Kennedy JL, Williams M, Nembhard W, Zoohoori N, Ruofel Du, **Jin J, Boothe D**, **Fischbach LA**, et al. State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020. PLOS ONE. 2022 Apr 27;17(4):e0267322.
doi: 10.1371/journal.pone.0267322. eCollection 2022.

Cardenas, VM; **Ali M**; **Fischbach, LA**, and Nembhard, WN. Dual use of electronic nicotine delivery systems during pregnancy and risk of small for gestational age. Annals of Epidemiology. 2020 Dec; 52:86-92.e2. doi: 10.1016/j.annepidem.2020.08.002. Epub 2020 Aug 15. ***Impact Factor: 2.804***

Fischbach L, Faramawi M, Girard D, **Thapa S**, Travers R. Training cosmetology students in Arkansas to help dermatologists find skin cancers earlier: Results of a cluster-randomized controlled trial. Journal of Public Health. July, 2020. https://doi.org/10.1093/pubmed/fdaa109. ***Impact Factor: 1.648***.

Cardenas VM, Cen R, **Clemens MM**, Moody HL, Ekanem US, Policheria A, **Fischbach LA**, Eswaran H, Magann EF, Delongchamp RR. Use of electronic delivery systems by pregnant women I: Risk of smallness for gestational age at birth. Tobacco Induced Diseases 2019;17:44 https://doi.org/10.18332/tid/106089. ***Impact Factor: 2.092***

Clemens MM, Cardenas V, **Fischbach LA**, **Cen R,** Siegal E, Hari E, Ekanem U, Policherla A, Moody H, Magann EF, Boysen G. Use of electronic delivery systems by pregnant women II: Hair biomarkers for exposures to nicotine and tobacco-specific nitrosamines. Submitted for publication in Tobacco Induced Diseases. Tobacco Induced Diseases. 2019;17:50 https://doi.org/10.18332/tid/105387. ***Impact Factor: 2.092***

Cardenas V, **Fischbach L,** Chowdhury P. Use of electronic nicotine delivery systems during pregnancy and its reproductive outcomes: A systematic review of the literature. Tobacco Induced Diseases 2019;17:44. ***Impact Factor: 2.092***

Thapa S, **Fischbach LA**, Delongchamp R, ElFaramawi M, Orloff M. Using machine learning to predict progression in the gastric precancerous process in a population with a high rate of gastric cancer who underwent an endoscopy. Gastroenterology Research and Practice 2019(7924):1-8. ***Impact Factor: 1.825***

Thapa S, **Fischbach LA**, Delongchamp R, Faramawi MF, Orloff M. The association between dietary salt intake and progression in the gastric precancerous process. Cancers 2019, 11(4), 467; https://doi.org/10.3390/cancers11040467. ***Impact Factor: 6.162***

Thapa S, **Fischbach LA**, Delongchamp R, ElFarfamawi E, Orloff M. The association between salt intake and potential mediators of the gastric precancerous process. Cancers 2019, 11, 535; doi:10.3390/cancers11040535. ***Impact Factor: 6.162***

Shewale AR, Barnes L, **Fischbach L**, Ounpraseuth S, Painter JP, Martin BC. Comparative effectiveness of low, moderate and high molecular weight hyaluronic acid injections in delaying time to knee surgery. *Journal of Arthroplasty*. 32(10):2952-2957.e21; 2017. http://dx.doi.org/10.1016/j.arth.2017.07.007. ***Impact Factor: 3.055.***

Shewale AR, Barnes L, **Fischbach L**, Ounpraseuth S, Painter JP, Martin BC. Comparative effectiveness of intra-articular hyaluronic acid and corticosteroid injections on time to surgical knee procedures. *Journal of Arthroplasty*. 32(12):3591-3597.e24; 2017. http://dx.doi.org/10.1016/j.arth.2017.07.007. ***Impact Factor: 3.055.***

Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone C, **Fischbach L**, Bazzoli F, Gisbert JP. Sequential versus standard triple first-line therapy for *Helicobacter pylori* eradication (Review*). Cochrane Database of Systematic Reviews*. 2016, Issue 6. Art. No.: CD009034. DOI: 10.1002/14651858.CD009034.pub2. ***Impact Factor: 5.939***.

Fallone CA, Chiba N, Veldhuyzen van Zanten S, **Fischbach L**, Gisbert JP, Hunt R et al. The Toronto Consensus for the Treatment of *Helicobacter pylori* Infection in Adults, *Gastroenterology* 151(1):51-69.e14;2016. doi: 10.1053/j.gastro.2016.04.006. ***Impact Factor: 16.716.***

Jadhav S, Chedijeu IP, Faramawi MF, Ndetan H, **Fischbach L**, **Thapa S**, Johnson ES. Non-cancer mortality in workers in the meat and delicatessen departments of supermarkets (1950-2006).[Erratum appears in Environ Res. 2015 Oct;142:764]

Johnson ES, Cardarelli K, Jadhav S, Chedjieu IP, Faramawi M, **Fischbach L** et al. Cancer Mortality in the Meat and Delicatessen Departments of Supermarkets (1950-2006). *Environment International* 77:70-75;2015. ***Impact Factor: 6.657.***

Faramawi MF, Delongchamp R, Lin YS, **Liu Y**, **Fischbach L**, Abouelenien S. Environmental lead exposure is associated with visit-to-visit systolic blood pressure variability in US adults. *International Archives of Occupational and Environmental Health* 88(3):381-8; 2015. ***Impact Factor: 2.196***.

Faramawi MF, **Fischbach L**, Delongchamp R, Cardenas V, Abouelenien S, Chedjieu IP, Taha N. Obesity is associated with visit-to-visit systolic blood pressure variability in the US adults. *Journal of Public Health*. Dec 15; 2014. PMID 25512372 ***Impact Factor: 2.456.***

Marin, AC. McNicholl, AG. Savarino, V. Calvet, X. Leontiadis, G. **Fischbach, L**. Yuan, Y. Gisbert, JP. Optimum second-line regimens for *Helicobacter pylori* eradication. *Cochrane Database of Systematic Reviews*. 10, 2014. Accession Number 00075320-100000000-09752. ***Impact Factor: 6.186.***

Fischbach L, Graham D, Kramer J, Rugge M, Verstovesek G, Parente P, et al. Association between *Helicobacter pylori* and Barrett's esophagus: a case-control study. *American Journal of Gastroenterology*. 109(3):357-68;2014*.* ***Impact Factor: 7.553***

Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse G, Calvet X, Fallone C, **Fischbach L**, Oderda G, Bazzoli F, Moayyedi P. Optimum duration of regimens for *Helicobacter pylori* eradication. *Cochrane Database of Systematic Reviews*. 12:CD008337, 2013***. Impact Factor: 6.186.***

Kramer JR, **Fischbach L**, Richardson P, Ramsey D, Alsarraj A et al. Waist to Hip Ratio but Not Body Mass Index is Associated with Increased Risk of Barrett's Esophagus in Caucasian Men. *Clinical Gastroenterology and Hepatology*. 11:373-81;2013. ***Impact Factor: 6.648***

Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone C, **Fischbach L**, Bazzoli F, Gisbert JP. Sequential versus standard triple therapy for *Helicobacter pylori* eradication [Protocol] \ C*ochrane Database of Systematic Reviews.* 3, 2013***. Impact Factor: 6.186.***

Fischbach LA, Nordenstedt H, Kramer JR, **Gandhi S, Dick-Onuoha S, Lewis A**, El Serag HB. The association between Barrett's Esophagus and *Helicobacter pylori* infection: A meta-analysis. *Helicobacter.* 17:163-75;2012. NLM. NIHMS343105. ***Impact Factor: 3.109.***

Graham DY, **Fischbach LA**. Empiric therapy of *Helicobacter pylori* infections. *Canadian Medical Association Journal*. 183:E506-8;2011. ***Impact Factor: 9.020.***

Prieto-Jimenez CA, Cardenas V, **Fischbach LA**, Mulla Z, Rivera J, Dominguez D, Graham DY, Ortiz M. Double-blind randomized trial of quadruple sequential *H. pylori* eradication therapy in asymptomatic, infected children in El Paso, Texas. *Journal of Pediatric Gastroenterology and Nutrition*. 52:319-25;2011. ***Impact Factor: 2.183.***

Rimbara E, **Fischbach LA**, Graham DY. Optimal therapy for *Helicobacter pylori* infection. *Nature Reviews Gastroenterology and Hepatology*. 8:79-88;2011. ***Impact Factor: 6.186.***

Yuan Y, Ford AC, Khan K, Forman D, Oderda G, Calvet X, Leontiadis GI, Fallone C, Gisbert JP, **Fischbach L**, Bazzoli F, Moayyedi P. Optimum duration of regimens for *Helicobacter pylori* eradication. *Cochrane Database of Systematic Reviews*. [Protocol] Issue 1;2010. ***Impact Factor: 6.186.***

Cervantes D, **Fischbach LA**, Goodman KJ, Phillips C, Chen S, **Broussard C**. Exposure *Helicobacter pylori*-positive siblings and persistence of *Helicobacter pylori* infection in early childhood. *Journal of Pediatric Gastroenterology and Nutrition.* 50(5):481-5;2010. ***Impact Factor: 2.183.***

Graham DYY, **Fischbach L**. *Helicobacter pylori* therapy in the era of increasing antibiotic resistance eradication. *Gut*. 59:1143-53;2010. ***Impact factor: 9.766.***

Ojha RP, **Fischbach LA,** Zhou Y Thertulien R. Acute myeloid leukemia following external beam radiation therapy for localized prostate adenocarcinoma: A population-based cohort study. *Cancer Epidemiology*. 34(3):274-8;2010. ***Impact factor: 1.182.***

Broussard CS, Goodman KJ, Nurgalieva ZZ, **Fischbach LA**, Gold BD. Exposure to antibiotics in a United States-Mexico border birth cohort. *Pediatrics* 125(6):e1468-74, 2010. ***Impact factor: 4.687.***

Forman, David. Bazzoli, Franco. Bennett, Cathy. Broutet, Nathalie. Chiba, Naoki. Deeks, Jonathan J. Fallone, Carlo. **Fischbach, Lori**. Hunt, Richard. Lahaie, Raymond. Laheij, Robert. Megraud, Francis. Moayyedi, Paul. Oderda, Giuseppina. Palli, Domenico. Savarino, Vincenzo. Misiewicz, (JJ) George. Unge, Peter. Gisbert, Javier P. Kuipers, Ernst J. Calvet, Xavier. Harris, Adam. Huang, J Q. Therapies for the eradication of *Helicobacter pylori*. *Cochrane Database of Systematic Reviews*. 4, 2009. ***Impact Factor: 6.186.***

Broussard CS, Goodman KJ, Phillips CV, Smith MA, **Fischbach LA**, Day RS, Aragaki CC. Antibiotics taken for other illnesses and spontaneous clearance of *Helicobacter pylori* infection in children. *Pharmacoepidemiology Drug Safety* 18(8):722-9;2009. ***Impact factor: 2.52***

Fischbach LA, Bravo LE, Zarama Rosero G, Bravo JC, **Ojha RP, Priest EL**, Collazos T, Casabon AL, Guerrero Zambrano L, Singh KP, Correa P**.** A randomized clinical trial to determine the efficacy of regimens containing clarithromycin, metronidazole, and amoxicillin among histological subgroups for *Helicobacter pylori* eradication in a developing country. *Helicobacter* 14:100-108;2009*.* ***Impact factor: 2.47***

Nurgalieva Z, Goodman KJ, Phillips CV, **Fischbach L**, de la Rosa M, Gold BD. Correspondence between *Helicobacter pylori* antibodies and urea breath test results in a US-Mexico birth cohort. *Pediatric Perinatal Epidemiology*. 22:302-312;2008**.** ***Impact factor: 1.83***

Ojha RP, Thertulien R, **Fischbach LA**. Racial under-representation in clinical trials: Consequence, myth, and proposition. *Epidemiologic Focus* 1(1):e2;2008.

Jain MK, Aragaki C, **Fischbach L**, Gibson S, Arora R, May L, Vardhineni K, Lee WM. Hepatitis C is associated with Type 2 diabetes mellitus in HIV-infected persons without traditional risk factors. *HIV Medicine*. *8(8):491-7;2007.* ***Impact factor: 2.67***

Fischbach LA, **Evans E**. Meta-Analysis: The effect of antibiotic resistance status on the efficacy of triple and quadruple. First-line therapies for *Helicobacter pylori. Alimentary Pharmacology and Therapeutics* 26:343357;2007. ***Impact factor: 3.71***

Khurana R, **Fischbach L,** Chiba N, Veldhuyzen van Zanten S, Sherman PM, George BA, Goodman KJ, Gold BD. Meta-Analysis of *Helicobacter pylori* treatment efficacy in children. *Alimentary Pharmacology and Therapeutics*. 25(5):523-36;2007. ***Impact factor: 3.71***

Long ZB, Oeffinger KC, **Fischbach LA**, Harris TR, Brooks SL, Eschelman DA, Tomlinson GA, Buchanan GR. Incidence and clinical relevance of abnormal complete blood counts in long-term survivors of childhood cancer. *Cancer*. 106(7):1634-40;2006. ***Impact factor: 4.58.***

Bourke B, Ceponis P, Chiba N, Czinn S, Ferraro R, **Fischbach LA**, Gold B, Hyunh H, Jacobson K,

Jones NL, Koletzko S, Lebel S, Moayyedi P, Ridell R, Sherman P, Veldhuyzen van Zanten S , Beck I, Best L, Boland M, Bursey F, Chaun H, Cooper G, Craig B, Creuzenet C, Critch J, Govender K, Hassall E, Kaplan A, Keelan M, Noad G, Robertson M, Smith L, Stein M, Taylor D, Walters T, Persaud R, Whitaker S, Woodland R. Canadian Helicobacter Study Group Consensus Conference: Update on the approach to *Helicobacter pylori* infection in children and adolescents--an evidence-based evaluation. *Canadian Journal of Gastroenterology* 19(7):399-408;2005. ***Impact factor: 2.03***

Khurana R, **Fischbach L**, Chiba N, Veldhuyzen van Zanten S. A current update on anti-*Helicobacter pylori* treatment in children. *Canadian Journal of Gastroenterology* 19(7):441-445;2005. ***Impact factor: 2.03***

Valente L, Caughy M, **Fischbach L**. A self-administered questionnaire to identify diabetics at increased risk for foot ulceration or amputation: A validation study. *Diabetes Educator* 30(6)932944;2004. ***Impact factor: 1.10***

Fischbach LA, Velhhuyzen Van Zanten S, **Dickason J**. Efficacy, adverse events and adherence related to first-line anti-*Helicobacter pylori* quadruple therapies: A meta-analysis. *Alimentary Pharmacology and Therapeutics* 20:1-12;2004. ***Impact factor from 2002-2006: 7.06***
Hunt R, Fallone C, Veldhuyzan van Zanten S, Canadian Helicobacter Study Group. Consensus Conference: Update on the management of *Helicobacter pylori:* An evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for *Helicobacter pylori. Canadian Journal of Gastroenterology* 18:547-554;2004. ***Impact factor: 2.03***

Fischbach LA, Correa P, Feldman M, Fontham E, **Priest EL**, Goodman KJ, Jain R. Increased reflux symptoms after calcium carbonate supplementation and successful *Helicobacter pylori* treatment: Results from a randomized clinical trial in a population with a high prevalence of multifocal atrophic gastritis. *Digestive Disease and Sciences* 48(8):1487-94;2003. ***Impact factor: 1.87***

Nash C, **Fischbach L**, Veldhuyzen Van Zanten S. What are the global response rates to *Helicobacter pylori* eradication therapy? *Canadian Journal of Gastroenterology* Suppl B:25B-29B;2003. ***Impact factor: 2.03***

Duffield-Lillico AJ, Reid ME, Turnbull BW, Slate EH, **Fischbach L**, Combs GF, Clark LC, Marshall J. Baseline characteristics and the effect of selenium supplementation on cancer risk in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. *Cancer Epidemiology Biomarkers and Prevention* 11:630-9;2002. ***Impact factor: 3.57*** **(The 14th most cited article from Cancer Epidemiology, Biomarkers and Prevention in 2002)**

Fischbach LA, Goodman KJ, Feldman M, Aragaki C. Sources of variation of *Helicobacter pylori* treatment success in adults worldwide: a meta-analysis. *International Journal of Epidemiology* 31(1):128-39;2002. ***Impact factor: 1.97***

Fischbach LA, Correa P, Ramirez H, Realpe J, Zarama G, Collazo T, Ruiz B, Schmidt B. Anti-inflammatory and tissue-protectant drug effects: Results from a randomized placebo-controlled trial of gastritis patients at high risk for gastric cancer. *Alimentary Pharmacology and Therapeutics* 15:831-41;2001. ***Impact factor: 7.06***

Spechler S, **Fischbach L**, Feldman M. Clinical Aspects of Genetic variability in *Helicobacter pylori*. *JAMA* 283(10):1264-66;2000. ***Impact factor: 23.18***

Forman D, Bazzoli F, Bennett C, Broutet N, Chiba N, Deeks JJ, Fallone C, **Fischbach L,** Hunt R, Lahaie R, Laheij R, Megraud F, Moayyedi P, Oderda G, Palli D, Savarino V, Misiewicz G, Unge P, Gisbert JP, Kuipers EJ, Calvet X, Harris A, Huang JQ. Therapies for the eradication of *Helicobacter pylori* [Protocol]. *Cochrane Database of Systematic Reviews* Issue 3. Art. No.: CD002298;2000. ***Impact Factor: 6.186.***

Schecter A, Dai LC, **Fischbach L**, Päpke O. Vietnamese Dioxin Blood and Milk Levels 1970-1999 and Implications for Future Epidemiological Studies. *Organohalogen Compounds* (44):417-23;1999.

Fischbach L, Lee D, Engelhardt R, Wheeler N. The prevalence of ocular disorders found among Hispanic and Caucasian children screened by the Mobile Eye Clinic. *Journal of Community Health* 18(4):201-11;1993. ***Impact factor: 1.21***.

Book Chapters

Fischbach L, Martin B. Cohort and Case Control Studies. In: Aparasu RR, Bentley JP, Eds, Principles of Research Design and Drug Literature Evaluation, 2nd Edition: Jones & Bartlett Learning, MA. 2019.

Fischbach L, Martin B. Cohort and Case Control Studies. In: Aparasu RR, Bentley JP, Eds, *Principles of Research Design and Drug Literature Evaluation,* 1st Edition: Jones & Bartlett Learning, MA: Burlington, 2015.

Van Zanten S., **Fischbach L**. *H. pylori* treatment effectiveness worldwide. In: Hunt RH, Tytgat GNT eds. *Helicobacter pylori: Basic Mechanisms to Clinical Cure 2003.* Dordrecht: Kluwer Academic Publishers, 2003.

Spotlighted Research

Student Names are highlighted

Fischbach LA, **Evans E**. Meta-Analysis: The Effect of Antibiotic Resistance Status on the Efficacy of Triple and Quadruple. First-Line Therapies for *Helicobacter pylori. Alimentary Pharmacology & Therapeutics*. 2007;26:343-357. In: Chiba N. Review: Quadruple therapies appear to be more effective than triple therapies for eradicating single-drug-resistant *Helicobacter pylori*. *American College of Physicians Journal Club.* 2008;148(1):9;2008.

Published Peer-Reviewed Letters to the editor

Student Names are highlighted

Fallone CA, Chiba N, Veldhuyzen van Zanten S, **Fischbach L**, Gisbert JP, Hunt R et al. Reply to: The Toronto Consensus in context. *Gastroenterology* 152(1):303-304;2017.

Shewale A, Fischbach LA, Hammond DA, Martin BC. Hyaluronic acid in Medicare knee osteoarthritis patients are associated with longer time to knee arthroplasty. *Journal of Arthroplasty*. 2017;32(2):696-697. doi: 10.1016/j.arth.2016.08.042. Epub 2016 Sep 29,2016

Alley L, Thapa S, Phelan B, Saylors M, Tiwari U, Sherrill J, **Fischbach L.** A biased review of the efficacy of commercial weight-loss programs. *Annals of Internal Medicine* 162(7);2015.

Graham DY, **Fischbach LA**. Letter: The ethics of using inferior regimens in *H pylori* randomized trials. *Alimentary Pharmacology and Therapeutics* 35(7):852-4; discussion 858;2012.

Graham DY, **Fischbach LA**. *Helicobacter pylori* infection. *New England Journal of Medicine*. 363(6):595-6;2010.

Cervantes DT. **Fischbach LA**. Gastric cardia adenocarcinoma in Taiwanese men: positive associations due to selection bias. *World Journal of Gastroenterology*. 16(12):1553-4;2010.

Graham DY, **Fischbach LA**. *Helicobacter pylori* infection: ethical considerations revisited. 44(7):523;2010. **Ojha RP**, Thertulien R, **Fischbach LA.** Re: Mortality Results from a Randomized Prostate-Cancer Screening Trial. *New England Journal of Medicine.* 361(2):203; authors reply 204-5;2009.

Evans EL, Ojha RP, **Fischbach LA**. Oral hypoglycemic use and the SANDS trial. *JAMA*. 300(4):389;2008.

Ojha RP, Felini MJ, **Fischbach LA**. Vitamin D for cancer prevention: valid assertion or premature anointment? *American Journal of Clinical Nutrition*. 86(6):1804-05;2007.

Ojha RP, **Cervantes D**, **Fischbach LA**. Oral pentoxifylline and pentavalent antimony for treatment of leishmaniasis: promising but inconclusive evidence of superiority, compared with antimony monotherapy. *Clinical Infectious Disease* 45(8):1104;2007.

Ojha RP, **Prabhakar D, Evans E, Lowery K**, Thertulien R, **Fischbach LA**. RE: Abou-Jawde et al. The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. *Haematologica* 92(3 Suppl):ELT01;2007.

Invited Presentations – State and Local

2018 *Training cosmetology students in Arkansas to help dermatologists prevent skin cancer and detect melanomas earlier*. Arkansas Department of Health, Grand Rounds. February 15.

2016 *Training cosmetology students in Arkansas to help dermatologists prevent skin cancer and detect melanomas earlier*. Arkansas Cosmetology Board. September 19.

2016 *Educational Intervention for Skin Cancer Prevention in Cosmetology Students.* Arkansas Cancer Coalition Quarterly Meeting. Cancer Arkansas Radiation Therapy Institute, Little Rock, AR. February 2.

2016 *Should corpus-predominant gastritis be used to identify H pylori positive patients at high risk for progression in the gastric precancerous process?* COPH Special Seminar.

2015 *Treatment of Helicobacter pylori*. Public Health Seminar

2013 *The Treatment of Helicobacter pylori: Using Evidence from Meta-analyses and Systematic Reviews to Change Clinical Guidelines*. Health Research, Policy and Health Promotion Seminar.

2013 *Skin Cancer Education for Cosmetology School Students*. Arkansas Department of Health, March, 17.

2012 *The Effect of Helicobacter pylori on Barrett's Esophagus*. UAMS Public Health Seminar, February 27.

2010 Invited Lecture on Meta-Analysis for UNTHSC, Medical School, Nov, 2010.

2008 Treatments for *Helicobacter pylori* for The GI Research Forum at Baylor College of Medicine, Feb, 2008.

2007 Panel on Ovarian Cancer – University of North Texas Health Science Center.

2005 Invited Lecture on Meta-analysis for the University of Texas Houston, Health Science Center

2004 *Conducting Public Health Research in Colombia* Invited Lecturer for the Public Health Elective, Southern Methodist University, Department of Anthropology, Spring Semester.

2003 *Conducting Public Health Research in a Developing Country* for the Public Health Elective, UT Southwestern Medical Center, School of Medicine, Sept 25.

2003 *Global Look at Medicine*, *Conducting Research in a Developing Country,* UT Southwestern Medical Center, School of Medicine, Dallas.

1998 *Cancer Prevention and Screening Seminar* – **In Spanish** (Project Ayuda, Tucson, AZ)

1991 – 1992 *Seminars on HIV Transmission* - **In Spanish** (Free Clinics in Los Angeles, California)

Invited Presentations – National and International

2017 **Keynote Presentation**. *Cancer Prevention in Nariño, Colombia*. 1st Annual Departmental Cancer Prevention Convention in Nariño, Colombia, October 5th (**In Spanish**).

2015 *The Best Helicobacter pylori Treatment for Countries with the Heaviest Burden of Infection: Results from a Meta-analysis of Studies from 43 Countries Worldwide.* 1st Annual World Congress of Digestive Diseases. December 17th in Nanjing, China.

2015 *Helicobacter pylori Treatment for Countries with the Heaviest Burden of Infection: Preliminary results from a meta-analysis of studies from developing countries.* CDC China. December 16th in Nanjing, China.

2015 *The Effect of Higher Doses for Proton Pump Inhibitors for Rescue Therapies*. Presentation for the North American Clinical Practice Guidelines for *Helicobacter pylori* Treatment. June 13th at the Toronto Consensus Meeting in Toronto, Canada.

2015 *Optimal Duration of Traditional Bismuth Quadruple Therapy as a Rescue Therapy.* Presentation for the North American Clinical Practice Guidelines for *Helicobacter pylori* Treatment. June 12th at the Toronto Consensus Meeting in Toronto, Canada.

2011 *Prospective cohort studies on gastric cancer in Colombia* – at the University of California Davis, December.

2011 *Helicobacter pylori – treatments and management* – Web seminar, Seattle, Washington, March, 2011.

2010 **State-of-the-Art Presentation**: *Clinical dilemmas in the treatment of Helicobacter pylori.* For the American Gastroenterology Association at Digestive Disease Week. May 2, 2010 **(which was selected to be taped and distributed to physicians around the world)**.

2010 *Helicobacter pylori as a risk factor for Gastric Cancer*, Universidad del Valle, School of Medicine, Cali, Colombia (In Spanish).

2005 *The effect of drug resistance on treatments for Helicobacter pylori*. Canadian Helicobacter Study Group Meeting, Consensus Conference, Montreal, Canada, Sept, 2005.

2004	*Treatments for Helicobacter pylori in Children*. Canadian Helicobacter Study Group Meeting, Consensus Conference Update, Ottawa, Canada, May 30 - June 2.
2003	**Keynote Speaker** *Quadruple therapy, effectiveness, side effects, pros and cons to being upgraded to first-line,* Canadian Helicobacter Study Group Meeting, Consensus Conference Update, Ottawa, Canada, May 30-June 1.
1993	*Helicobacter pylori Infection. Associated Diseases and Hygiene* (Pasto, Colombia) (On Spanish).
1986 – 1988	*Prevention of the Ten Leading Causes of Childhood Morbidity and Mortality in Colombia* (Bogotá, Colombia) (In Spanish).
1986 – 1988	*Preventing Malnutrition in Young Children in Bogotá, Colombia*. (In Spanish).

Presentations Resulting in a Published Abstract

Student Names and Student Awards are highlighted

Nyssen OP, Marin AC, McNicholl AG, Savarino V, Calvet Calvo X, Leontiadis GI, **Fischbach L** et al. Optimum second-line regimens for *Helicobacter pylori* eradication: Interim results of an on-going Cochrane Systematic Review. United European Gastroenterology Week, Barcelona, Spain. (October, 2019).

Gu M, Patil N, **Fischbach LA**, Mukasa L. Integration of Tuberculosis (TB) Screening in The Ryan White Program in Arkansas. *Open Forum Infectious Diseases* 4(suppl_1):S209-S210, October, 2017.

Shewale AR, Barnes LC, **Fischbach LA**, Ounpraseuth S, Painter JT, Martin BC. "Characterization of initial treatment strategies used to manage incident knee osteoarthritis. A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Washington, DC, USA. May 24, 2016. (*Value in Health,19(3),A238).*

Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone C, **Fischbach L,** Bazzoli F, Gisbert JP. Meta-analysis of sequential vs standard triple therapy for *Helicobacter pylori* eradication: final results of a Cochrane Systematic Review. European Helicobacter Study Group XXCIIth International Workshop on Helicobacter & Microbiota in Inflammation & Cancer. United European Gastroenterol J 2014 Oct; 2(1 Suppl):

Powell T, **Ojha RP**, Singh KP**, Fischbach LA.** Histologic subtype and pancreatic cancer survival: addressing uncontrolled confounding. *Annals of Epidemiology* 19(9):673;2009 ***2nd Place in the Student Poster Competition at the American College of Epidemiology Conference.**

Ojha RP, **Fischbach LA**, Singh KP, Thertulien R. The utility of a multivariable approach to screening bone metastasis among newly diagnosed prostate cancer patients in the United States. *Annals of Epidemiology* 19(9):672;2009.

Evans EL, Ojha RP, Fischbach LA. The association between vitamin C deficiency and type 2 diabetes for subjects with and without a family history of diabetes. *Annals of Epidemiology*. 19(9):652;2009.

Ojha RP, Evans EL, Thertulien R, **Fischbach LA**. Survival of pediatric and adolescent osteosarcoma patients in the United States after adjuvant external beam radiation therapy. *American Journal of Epidemiology*. 169(Suppl):S52;2009 (Abstract 208-S).

Powell TN, Pendurthis MK, **Ojha RP, Evans EL, Fischbach LA.** Temporal comparison of analyses using correlation coefficients for estimating associations in ecologic studies of cancer etiology: A systematic review. *American Journal of Epidemiology* 169(Suppl):S48;2009 (Abstract 190-S).

Evans EL, Ojha RP, Fischbach LA. Salient characteristics for recommending glucose testing to identify pre-diabetic adults aged <45 years in the United States. *American Journal of Epidemiology* 169(Suppl):S2;2009 (Abstract 007-S).

Ojha RP, Singh KP, Felini MK, **Evans EL, Fischbach LA.** Best subset selection and trend analysis for optimizing the discriminatory accuracy of diagnostic models. *Annals of Epidemiology* 18(9):732;2008 (*Abstract*) ***1st Place in the Student Poster Competition at the American College of Epidemiology Conference.**

Evans EL, Ojha RP, **Fischbach LA**. Non-invasive diagnostic models to identify undiagnosed diabetics and factors divergent from diagnosed diabetics. *Annals of Epidemiology* 18(9):732;2008.

Evans EL, Ojha RP, Zhou Y, Fischbach LA. Determinants of diabetic patient non-compliance to physician-recommended weight loss in the United States. *Diabetes*. 2008, June; Suppl..

Ylitalo KR, Ojha RP, Evans EL. **Fischbach LA**, Felini MJ. Race-specific predictors of breast cancer risk among screened postmenopausal women in the United States. *American Journal of Epidemiology* 167(11):S7;2008 (*Abstract*).

Ojha RP, Fischbach LA, Evans EL, Thertulien R . Race-specific modeling of prostate-specific antigen and prevalent bone metastasis among newly diagnosed, untreated prostate adenocarcinoma patients. *American Journal of Epidemiology*. 167:253-S;2008.

Evans EL, Ojha RP, **Fischbach LA**. The role of hypertension in the independent associations of diabetes and obesity with renal cell cancer. *American Journal of Epidemiology* 167(11):S80;2008

Ojha RP, Thertulien R, Zhou Y, **Fischbach LA**. Prostate cancer treatment and risk of acute myeloid leukemia in a population-based prospective cohort. *Journal of Clinical Oncology*. 26:*Abstract* 5073;2008.

Ojha RP, Thertulien R, **Prabhakar D**, Zhou Y, **Fischbach LA**. A comparative investigation of therapeutic approaches for primary prostate cancer and risk of acute myeloid leukemia. *Blood*. 110:(*Abstract* 1816);Nov,2007.

Ojha RP, Zhou Y, **Fischbach LA**, Phillips MM, Thertulien R. An ecologic perspective of multiple myeloma incidence: Heterogeneous effects of industrial exposures and socioeconomic status. *Annals of Epidemiology* 17(9):730;Sep,2007 (*Abstract*).

Broussard CS, Goodman KJ, Phillips CV, Day RS, Aragaki CC, Smith MA, **Fischbach LA.** Antibiotics taken for other illnesses and incidence of *Helicobacter pylori* infection in children. *Annals of Epidemiology* 2007;165(11):S125;2007 ***1st Place in the Student Poster Competition at the American College of Epidemiology Conference.**

Broussard CS, Goodman KJ, Phillips CV, Smith MA**, Fischbach LA,** Aragaki CA, Day RS. Exposure to antibiotics in a US-Mexico birth cohort *American Journal of Epidemiology* 163(11):S37;2006.

Goodman DK, O'Rourke K, Day RS, **Fischbach LA** et al. Helicobacter pylori infection rates in the first four years of life: US-Mexico cohort study. *American Journal of Epidemiology* 163(11):S34;2006.

Cervantes D, **Fischbach L**, Goodman KJ, Cardenas V. Exposure to *H. pylori*-positive siblings and persistence of *H. pylori* in early childhood. *American Journal of Epidemiology* 163(11):S12;2006.

Phillips CV, Guenzel B, **Fischbach LA**, et al. Amplified in the telling; How dubious claims evolve into conventional wisdom. *American Journal of Epidemiology* 159(11):S31;2004.

Priest EL, **Fischbach LA**. *Helicobacter pylori* infection and non-ulcer dyspepsia in a Colombian population. *American Journal of Epidemiology* 55(11):S43(169);2002.

Aragaki C, **Jones CP**, del Junco DJ, **Fischbach LA**. Gene-environment interaction estimation methods and strategies: a review and proposal. *American Journal of Epidemiology* 55(11):S49(193);2002.

Aragaki C, **Fischbach LA**, Field C, et al. An internet-based tool for patient-based decision analysis: application to severe persistent asthma. *American Journal of Epidemiology* 55(11):S4(013);2002.

Fischbach LA, **Lenz C**, **Priest EL**. Adverse events of triple therapy to eliminate *Helicobacter pylori* are similar to placebo: results from a randomized placebo-controlled clinical trial. *International Journal of Medical Microbiology*. 291(Suppl 31):57(G-04);2001.

Priest EL, **Fischbach LA**. Elimination of *Helicobacter pylori* is not associated with resolution of nonulcer dyspepsia: results from a randomized placebo-controlled clinical trial in Colombia. *International Journal of Medical Microbiology*. 291(Suppl 31):52-53(F-29);2001 (*Abstract*).

Priest EL, **Fischbach LA**. Density of *Helicobacter pylori* infection and height, weight and BMI in a Colombian population. *American Journal of Epidemiology* 153(11):S210;2001.

Clark LC, Combs GF, Turnbull BW, Slate EH, **Fischbach L**, Duffield-Lillico AJ, Marshall JR, Dalkin BL, Reid ME. Subgroup analysis of the nutritional prevention of cancer with selenium trial: A randomized clinical trial. *Cancer Epidemiology Biomarkers & Prevention* 10(2):155;2001.

Fischbach L, Goodman K. Predictors of *Helicobacter pylori* Treatment Success: A Review of the Literature. *American Journal of Epidemiology* 149(11):S12(46);1999.
Fischbach L, Correa P, Schmidt B, Ramirez H, Casabon A. Predictors of *Helicobacter pylori* clearance after triple therapy in Colombia. *American Journal of Epidemiology* 145(11):S43(169);1997.

Fischbach L, Correa P, Schmidt B, Ramirez H, Ruiz B. A randomized clinical trial to evaluate polymorphonuclear leukocyte infiltrate (PMN) as an intermediate in the pathway of *H. pylori* infection resulting in epithelial damage. *Gut* 41(Suppl 1):A28(02/98);1997.

Araya JC, **Fischbach L,** Bravo JC, Schmidt B, Correa P. Cell proliferation in atrophic gastritis: Effect of anti-*Helicobacter pylori* treatment and calcium supplementation. *Modern Pathology* 9(1):54A;1996.

Fischbach L, Engelhardt R, Lee D. The prevalence of ocular disorders found among Hispanic and Caucasian 5 to 8 year olds screened by the UCLA Mobile Eye Clinic. *Investigative Ophthalmology & Visual Science* 32(4):1154;1991.

Other Conference Presentations

Student Names and Awards are highlighted

Fischbach L, Thapa S, Cardenas V, Shewale A, Azam M, Zhang Q, Gu M, Chedjieu I, Surani S. *Helicobacter pylori* treatment effectiveness in developing countries: Research Day Abstract Presentations, 2018.

Gu, M., Patil, N., Fischbach, L., et al. (May, 2018). Integration of Tuberculosis (TB) Screening in The Ryan White Program in Arkansas. 2018 National TB Conference, Rancho Mirage, CA.

Gu, M., Mukasa, L., et al. (May, 2018). Targeting the Birth-Cohort of the Pre-Antibiotic Era: A Proposal to Screen for Tuberculosis in Seniors in Arkansas. 2018 National TB Conference, Rancho Mirage, CA.

Gu, M*.,* Patil, N., **Fischbach, L***.,* et al. (October, 2017). *Integration of Tuberculosis (TB) Screening in The Ryan White Program in Arkansas*. Poster session presented at the Infectious Disease Week 2017, San Diego, CA.

Gu, M., Patil, N., **Fischbach, L**., et al. (June, 2017). *Tuberculosis Screening Among HIV-Infected Population in the United States: Preliminary Findings.* Poster session presented at the Society for Epidemiologic Research 2017 Meeting, Seattle, WA.

Gu, M., Patil, N., **Fischbach, L**., et al. (May, 2017). *Tuberculosis Screening Among HIV-Infected Population in the United States: Preliminary Findings.* Poster session presented at the Arkansas Public Health Association 2017 Meeting, Little Rock, AR.

Gu, M., Patil, N., **Fischbach, L.**, et al. (April, 2017). *Tuberculosis Screening Among HIV-Infected Population in the United States: Preliminary Findings*. Poster session presented at the National TB Conference, Atlanta, GA.

Shewale AR, Barnes LC, **Fischbach LA**, Ounpraseuth S, Painter JT, Martin BC. (May 22, 2017) *Conflicting comparative effectiveness evidence of Hyaluronic acid using real world evidence: An update using a high dimensional propensity score matching approach*. International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting. Boston, Mass.

Gu, M., Patil, N., **Fischbach, L.**, et al. (October, 2016). *Tuberculosis Screening Among HIV-Infected Population in the United States: Preliminary Findings*. Poster session presented at the Infectious Disease Week 2016, New Orleans, LA.

Fischbach L, **Thapa S**, Bravo LE, Casabon AL, Orloff M, Franco A, Cardenas V, El Faramawi M, **Prowse H, Hunter M**. (September 11, 2016) *Is corpus-predominant gastritis a stronger risk factor than atrophic gastritis for progression to intestinal metaplasia, dysplasia and gastric cancer? Results from a 12-year prospective follow-up in Pasto, Colombia*. Presented in English and Spanish at the Panamerican Digestive Disease Week, Cartagena, Colombia. **Awarded the Gold Star Award for the conference**.

Shewale AR, Barnes LC, **Fischbach LA**, Ounpraseuth S, Painter JT, Martin BC. (May 21-25, 2016) *Characterization of initial treatment strategies used to manage incident knee osteoarthritis*. Presented at the 21st International Society Pharmacoeconomics and Outcomes Research Conference. Washington DC.

Shewale A, Stolarz A, Painter J, Rusch N, Shah A, **Fischbach L**. (October, 2015) *Risk of arm lymphedema with Taxane and Anthracycline use among patients with breast cancer*. Society for Medical Decision Making (SMDM) conference.

Shakhatreh M, Katz L, El Faramawi M, El-Serag H, **Fischbach L**. (May, 2014) *The association of obesity and Barrett's esophagus.* Digestive Disease Week, Chicago, IL.

Fernando S, Bangara S, Chisty Z, **Fischbach LA.** (May, 2012) *The association between dietary salt intake and gastric cancer progression & regression*. Digestive Disease Week, San Diego, CA.

Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone CA, **Fischbach LA**, Bazzoli F, Gisbert JP. (May, 2012) *Meta-analysis of sequential vs standard triple therapy for Helicobacter pylori eradication*. Digestive Disease Week, San Diego, CA.

Kramer JR, **Fischbach LA**, Richardson P, Ramsey DJ, Alsarraj A, Fitzgerald SJ, Shaib YH, Abraham N, Velez ME, Cole RA, Anand BS, Graham D, El-Serag H. (May, 2012) *Association of high risk waist-to-hip ratio with Barrett's Esophagus, and their interaction with race/ethnicity*. Digestive Disease Week, San Diego, CA.

Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone CA, **Fischbach LA**, Bazzoli F, Gisbert JP. (September 11-13, 2011) *Meta-analysis of sequential vs standard triple therapy for Helicobacter pylori*. XXIVth International Workshop of the Helicobacter Study Group, Dublin, Ireland.

Priest EL, Adams B, **Fischbach LA**. (March 22-25, 2009) *Easier exploratory analysis for epidemiology: A grad student how-to-paper*. SAS Global Forum. Washington D.C.. ***Best Contributed Paper in Statistics, SAS Global Forum, Washington D.C., 2009.**

Prabhakar D, **Fischbach LA**, **Ojha, RP**. (November, 2007) *Obesity and premenopausal breast cancer mortality rates in the United States: A racially stratified ecologic analysis.* American Public Health Association Conference, Washington DC.

Broussard CS, Goodman KJ, Phillips CV**, Fischbach LA,** Aragaki CC**.** (November, 2007) *Spontaneous clearance of Helicobacter pylori infection in a US-Mexico birth cohort.* American Public Health Association Conference.

Fischbach LA, Bravo LE, Casabon AL, Zarama Rosero G, **Ojha RP, Priest E**, Guerrero Zambrano L, Collazo T, Correa P. (May 22, 2007)*14-day Treatment with Clarithromycin, Metronidazole and Amoxicillin for the Eradication of Helicobacter pylori in Pasto, Colombia*. Digestive Disease Week Meeting in Washington, DC.

Broussard CS, Goodman KJ, Bin Saeed A, Nurgalieva Z, **Fischbach LA**. (May November 4-8, 2006) *Exposure to antibiotics in a US-Mexico birth cohort*. American Public Health Association Conference & Exposition in Boston, MA.

Broussard CS, Goodman KJ, Bin Saeed A, Nurgalieva Z, **Fischbach LA**. (June, 2006) *Exposure to antibiotics in a US-Mexico birth cohort.* North American Congress of Epidemiology in Seattle, Washington.

Cervantes D, **Fischbach L**, Goodman KJ, Cardenas V. (June, 2006) *Exposure to H. pylori-positive siblings and persistence of H. pylori in early childhood*. North American Congress of Epidemiology in Seattle, Washington.

Fischbach LA, **Evans E**. (September, 2005) *The Effect of Antibiotic Resistance Status on the Efficacy of Triple and Quadruple First-Line Therapies for Helicobacter pylori Infection: A meta-analysis.* Canadian Helicobacter Study Group Meeting. Montreal, Canada.

Fischbach LA, Velhhuyzen Van Zanten S, **Dickason J**. (May, 2004) *Efficacy, Adverse Events and Adherence Related to First-Line Anti-Helicobacter pylori Quadruple Therapies:* A Meta-Analysis (Poster Presentation)**.** Digestive Disease Week Conference in New Orleans, LA.

Fischbach LA. *Anti-Helicobacter pylori treatment in children*. (May, 2004) **Speaker at the Pediatric Canadian Consensus Conference,** Canadian Helicobacter Study Group Meeting, Consensus Conference Update, Ottawa, Canada.

Fischbach LA Velhhuyzen Van Zanten S, **Dickason J**. (May, 2004) *Efficacy, Adverse Events and Adherence Related to First-Line Anti-Helicobacter pylori Quadruple Therapies: A Meta-Analysis* (Poster Presentation). Digestive Disease Week Conference in New Orleans.

Fischbach LA, **Lenz C, Priest E**, Correa P. (November, 2002) *Adverse events of triple therapy to eliminate Helicobacter pylori are similar to placebo: Results from a randomized placebo-controlled clinical trial. Helicobacter pylori*: Basic mechanisms to clinical cure 2002 conference in Maui, Hawaii.

Aragaki C, Coyle YM, **Fischbach LA**, Gareen IF, **Field CA**, Culica DV, Hynan LS, **Mercer Q,** Gatchel RJ. (November, 2001) *A new method for health related quality of life analysis: An internet-based tool for patient-based decision analysis* [poster]. University of Texas Houston Research Day.

Fischbach LA, **Priest EL**. (September, 2001) Helicobacter pylori infection and non-ulcer dyspepsia in a Colombian population. International Workshop on *Campylobacter, Helicobacter and Related Organisms*, Freiburg, Germany.

Aragaki C, **Fischbach LA**, **Field C**, Culica D, **Mercer Q**, Hynan L, Gatchel R, Gareen I, Coyle YM. *A new method for analyzing quality of life: Application to severe persistent asthma* [poster]. Causal Inference Conference, Colorado, August, 2001.

Fischbach L, Reid ME, Clark LC, Combs GF, Turnbull BW, Marshall JR. (May, 2001) *Daily supplementation at 400microgms of selenium: Are there potential toxic effects? Results from a double-blind, placebo-controlled, randomized clinical trial*. ASPO. Session I: Cancer Epidemiology/ Chemoprevention/ Biomarkers/Genetics. NY, New York.

Fischbach L, Goodman KJ, Feldman M. *When are antibiotic therapies effective at eliminating Helicobacter pylori infection? When aren't they not? A meta-analysis*. *Helicobacter pylori*: Basic mechanisms to clinical cure 2000 conference, Bermuda, 2000.

Khurana R, **Fischbach L**, **George B**, Goodman KJ. *A review of Helicobacter pylori treatment in children*. *Helicobacter pylori*: Basic mechanisms to clinical cure 2000 conference, Bermuda, 2000.

Fischbach L and Goodman K. (February, 1998) *A review of treatment success in populations of varying Helicobacter pylori prevalence and drug resistance*. North American *Helicobacter pylori* conference in Phoenix, AZ.

Fischbach L, Correa P, Schmidt B, Ramirez H, Casabon A. (November, 1997) *Predictors of Helicobacter pylori clearance after triple therapy in Colombia.* American Public Health Association Conference, Indianapolis, Indiana.

Fischbach L, Correa P, Schmidt B, Ramirez H, Ruiz B. (September, 1997) *Helicobacter pylori associated chronic gastritis and epithelial damage*. Annual Scientific Sessions for the American College of Epidemiology, Cambridge, Mass.

Fischbach L, Correa P, Schmidt B, Ramirez H, Ruiz B. (September, 1997) *A randomized clinical trial to evaluate polymorphonuclear leukocyte infiltrate (PMN) as an intermediate in the pathway of H. pylori infection resulting in epithelial damage*. International Workshop on Gastroduodenal Pathology and *Helicobacter pylori*, Lisbon, Portugal.

Fischbach L, Correa P, Schmidt B, Ramirez H, Casabon A. (June, 1997) *Predictors of Helicobacter pylori clearance after triple therapy in Colombia*. Paper presented at the annual meeting of the Society for Epidemiologic Research, Edmonton, Canada.

Quinn EA, Ramos LJ, Martinez M, **Fischbach L**. AIDS literacy: Developing effective educational materials for Latina women with low literacy skills. IXth International Conference on AIDS in affiliation with the IVth STD World Congress 102;1993.

Ramos LJ, **Fischbach L**, Samaniego L et al. The Latinas and AIDS Research Project: Exploring the differences in AIDS sexual knowledge, beliefs and behaviors for Mexican, Mexican American, and white women of different sexual orientations and sexual behavior groups in Los Angeles County 19871992. IXth International Conference on AIDS in affiliation with the IVth STD World Congress 121;1993.

Fischbach L, Lee D, Engelhardt R, Wheeler N. (May, 1991) *The prevalence of ocular disorders found among Hispanic and Caucasian children screened by the Mobile Eye Clinic*. Paper presented at the annual meeting of the Association for Research in Vision and Ophthalmology, Sarasota, Florida.

Funded Grants and Contracts

Mentor	Predoctoral Training in Advanced Data Analytics for Behavioral and Social Sciences Research NIH T32 MD015016-01
Co-Investigator	Arkansas Coronavirus Seroprevalence Study. Contract with the State of Arkansas using Federal Funding. Total Funds: $3,300,000. Dates: 6/2020 – 11/2020.
Program Director	Doctoral Student Trainee Contract. Arkansas Department of Health Total Funds ranged from $24,000-$50,000 in stipends per year plus tuition. 8/2015-6/2021.
Principal Investigator	*Pilot Intervention to Increase use of the Arkansas Tobacco Quitline in Rural Arkansas.* Arkansas Cancer Coalition. Total Funds: $1,000. Dates: 3/6/2017-5/21/2017.
Principal Investigator	*24-year follow-up study to identify Helicobacter pylori strains associated with the incidence of gastric precancerous lesions or gastric cancer in Pasto, Colombia.* Cancer Institute – UAMS Total Funding: $78,563.
Principal Investigator (co-PI)	*Training cosmetology students in Arkansas to help dermatologists prevent skin cancer and detect melanomas earlier*. Arkansas Cancer Coalition. Total Funding: $55,000. 11% FTE. Dates: 7/1/2016-6/30/2017.
Principal Investigator (co-PI)	*Skin Cancer Education for Cosmetology Students in Arkansas.* Arkansas Cancer Coalition. Total Funds: $2,500. Dates: 9/1/2015-12/17/2015.

Principal Investigator	*A Retrospective cohort study to examine the efficacy of treatments for pressure ulcers in nursing home populations - Phase II*. HealthPoint Contract. Funding suspended due to the Department of Justice judgment against HealthPoint. Dates: 12/2012.
Principal Investigator	*A Retrospective cohort study to examine the efficacy of treatments for pressure ulcers in nursing home populations - Phase I*. HealthPoint Contract. Funding suspended due to the Department of Justice judgment against HealthPoint. Total Funds: $38,000. Dates: 2011-2012.
Principal Investigator	*Inhibition of the Inflammatory and Gastric Pre-malignant Process by Subantimicrobial Doxycycline*. Competitive Institutional Seed Research Grant. Total Funds: $60,000.
Subcontract, PI	*Obesity, H. pylori and Risk of Barrett's Esophagus* (RO1- National Institute of Health) (PI: Hashem El Serag). Total funding: $2,818,335. Dates: 2007-2012.
Consultant	*Randomized field intervention trial of H. pylori eradication to reduce iron deficiency among children in El Paso, Texas*. The Trasher Foundation. Total Funding: $350,077. Dates: 2006-2008.
Subcontract, PI	Training Curriculum in Patient Oriented Research. National Institute of Health – K30. Subcontract: $35,691 + 15% salary at UT Houston. Dates: 2004-2007.
Principal Investigator	*Preliminary Studies to Investigate the Effect of anti-H. pylori Treatment on Non-ulcer Dyspepsia, Gastroesophageal Reflux Disease, Erosive Esophagitis, Barrett's Esophagus, and Gastric Precancerous Lesions.* UNTHSC – Intramural Seed Grant. Total Funding: $10,000. Dates: 2006.
Co-Investigator	*H. pylori Infection in Children on the US-Mexico Border*. National Institute of Health – RO1 (National Institute of Diabetes and Digestive and Kidney Diseases) (PI: Goodman KJ). Total Funding: $1,329,054. Dates: 2003-2006.
Subcontract, PI	Patient Oriented Research Project. National Institute of Health – K30. Total Funding: $925,810. Dates: 1999-2004.
Fellow	*Study of the Effects of Selenium Supplementation on Progression of Prostate Cancer.* Cancer Research Foundation of America. Total funding: $29,700. Dates: 1998.
Research Associate	*Phase II Study of the Effect of Selenium Supplementation on Progression of Prostate Cancer*. International Cancer Alliance. Total Funding: $240,000. Dates: 1997-1998.

Research Associate	*Phase III Trial of Selenium for Cancer Prevention*. National Cancer Institute. Total Funding: $4,986,480. Dates: 1997-1998.
Research Associate	*Chemoprevention Trial of Selenium and Prostate Cancer*. Department of Defense. Total Funding: $400,000. Dates: 1997-1998.
Principal Investigator	*Treatments for Helicobacter pylori associated chronic gastritis: A randomized clinical trial and a meta-analysis*. Wiseman Memorial Fund Grant. Total Funding: $10,000. Dates: 1993-1997.
Principal Investigator	*Helicobacter pylori* associated chronic gastritis in populations with a high clinical trial. Fulbright Scholar Award for Research. Total Funding: $30,000. Dates: 1993-1994.

References

Mohammed Orloff PhD
Associate Professor of Epidemiology
University of Arkansas for Medical Sciences
MSOrloff@uams.edu
Phone: 216-235-7134

Mohammed El Faramawi MD, PhD
Associate Professor of Epidemiology
University of Arkansas for Medical Sciences
MElfaramawi@uams.edu
Phone: 501-766-8469

Karan Singh PhD
Chair, Department of Epidemiology and Biostatistics
University of Texas at Tyler
karan.singh@uthct.edu
(903) 877-1403

Barbara Fuhrman PhD
Research Scientist, Center for Adolescent and Young Adult Health Research
University of Pittsburgh / UPMC
fuhrmanbj@upmc.edu
716-829-9160

Kelley Garner (Student)
Arkansas Department of Health
4815 West Markham Street
Little Rock, AR
Kelley.garner@arkansas.gov
501-765-6049

Leanna Delhey, MPH (student)
Graduate Assistant
University of Arkansas for Medical Sciences
Little Rock, AR
ldelhey@uams.edu
724-645-7729

Susan Thapa, PhD (former student)
Assistant Professor
Washington University
thpssn@gmail.com
501-612-8681